PE20011024A1 - Dispositivo transdermico de reboxetina, uso y metodo - Google Patents

Dispositivo transdermico de reboxetina, uso y metodo

Info

Publication number
PE20011024A1
PE20011024A1 PE2000001219A PE0012192000A PE20011024A1 PE 20011024 A1 PE20011024 A1 PE 20011024A1 PE 2000001219 A PE2000001219 A PE 2000001219A PE 0012192000 A PE0012192000 A PE 0012192000A PE 20011024 A1 PE20011024 A1 PE 20011024A1
Authority
PE
Peru
Prior art keywords
effect
reboxetin
transdermal device
matrix
refers
Prior art date
Application number
PE2000001219A
Other languages
English (en)
Inventor
Ulla Hoeck
Helle Kristensen
Bo Kreilgaard
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of PE20011024A1 publication Critical patent/PE20011024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN DISPOSITIVO TRANSDERMICO DE REBOXETINA (2-(O-(2-ETOXIFENOXI)BENCIL)-MORFOLINA); DESPROVISTO DE UNA MATRIZ COMPRENDIENDO GEL; CARACTERIZADO PORQUE PROPORCIONA UNA DOSIFICACION DIARIA DE 0,1 MG A 20 MG; DURANTE UN PERIODO DE TIEMPO DE12, 24, 48 HORAS O HASTA 7 A 14 DIAS; AUMENTA LA PENETRACION TRANSDERMICA; REDUCE LAS REACCIONES IRRITANTES; EL DISPOSITIVO ES DEL TIPO DEPOSITO, MATRIZ, FARMACO EN ADHESIVO, MULTILAMINADO, SISTEMA DE POLIMERO SIN PAPEL METALIZADO, IONTOFORETICO, ELECTROPORACION, ELECTROOSMOSIS, ELECTROINCORPORACION, INYECCION POR MEZCLA; TAMBIEN SE REFIERE A UN COMPLEJO DE REBOXETINA Y ß-CICLODEXTRINA. EL DISPOSITIVO TRANSDERMICO ES UTIL PARA OBTENER UN EFECTO ANTIDEPRESIVO, EFECTO ANTIRESERPINA Y EFECTO DE INHIBICION DE LA REINCORPORACION DE LA NORADRENALINA Y PUEDE SER UTIL PARA TRATAR DESORDENES ADITIVOS, SINDROMES DE ABSTINENCIA, DESORDENES MENTALES Y DE APRENDIZAJE
PE2000001219A 1999-12-23 2000-11-15 Dispositivo transdermico de reboxetina, uso y metodo PE20011024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904750A SE9904750D0 (sv) 1999-12-23 1999-12-23 New formulation, use and method

Publications (1)

Publication Number Publication Date
PE20011024A1 true PE20011024A1 (es) 2001-10-03

Family

ID=20418276

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001219A PE20011024A1 (es) 1999-12-23 2000-11-15 Dispositivo transdermico de reboxetina, uso y metodo

Country Status (7)

Country Link
EP (1) EP1244431A1 (es)
AR (1) AR026371A1 (es)
AU (1) AU1068101A (es)
MY (1) MY133485A (es)
PE (1) PE20011024A1 (es)
SE (1) SE9904750D0 (es)
WO (1) WO2001047503A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286669B6 (sk) 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie
EP1459750B1 (en) * 1999-07-01 2005-06-01 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
DE102017127433A1 (de) 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
TW202016088A (zh) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺
EP3584244A1 (en) 2018-06-20 2019-12-25 UCB Pharma GmbH Substituted alkoxypyridinyl indolsulfonamides
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
ES2969383T3 (es) 2019-06-17 2024-05-17 Ucb Pharma Gmbh Derivados de N-(fenil)-indol-3-sulfonamida y compuestos relacionados como moduladores de GPR17 para el tratamiento de trastornos del SNC tales como la esclerosis múltiple

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5155198A (en) * 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent

Also Published As

Publication number Publication date
AR026371A1 (es) 2003-02-05
WO2001047503A1 (en) 2001-07-05
EP1244431A1 (en) 2002-10-02
SE9904750D0 (sv) 1999-12-23
AU1068101A (en) 2001-07-09
MY133485A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
PE20011024A1 (es) Dispositivo transdermico de reboxetina, uso y metodo
DE69623608T2 (de) Zusammensetzung zur verbesserten elektroübertragunslieferung von wirkstoff
AUPR148400A0 (en) Apparatus for delivery of pharmaceuticals to the cochlea
ES2106045T3 (es) Sistema de tratamiento por iontoforesis.
GR1001025B (el) Μεθοδος δια διαδερμικην (υποδοριον παροχην ibuprofen, δια χρησιμοποιησεως υδραλκοολικου πυκτωματος (γελης).
DE69326461D1 (de) Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung
MX9302812A (es) Administracion transdermica de oxibutinina.
ATE155045T1 (de) Vorrichtung zur verabreichung von heilmitteln
MX342007B (es) Composicion de farmaco conjugado.
PT1003477E (pt) Sistema terapeutico transdermico (tts), contendo polimeros de (met)acrilato com grupos amonio para administracao de levonorgestrel
CY1107923T1 (el) Τυποποιησεις ελεγχομενης απελευθερωσης χορηγουμενες απο του στοματος
GB2317569A (en) Device for transdermal electrotransport delivery of fentanyl and sufentanil
NZ332746A (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease
DK0818973T3 (da) Bionedbrydelig indretning
ATE253910T1 (de) Transdermale verabreichung von lasofoxifen
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
HK1046847B (zh) 包括撲熱息痛和丁螺環酮的止痛藥物組合
PT96045A (pt) Sistema transcutaneo aperfeicoado para aplicacao de compostos farmacologicamente activos em condicoes de ph controlado
BR9406900A (pt) Sistema de transporte transdermal molecular
Oh Transdermal delivery of ketoprofen and the effect of electroosmosis
LV10749A (lv) Transdermala terapeitiska sistema fizostigmina uzliksanai uz adas un tas izgatavosanas panemiens
ATE269063T1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam

Legal Events

Date Code Title Description
FC Refusal